The actions of government regulatory agencies have contributed to declines in research productivity, discouraged investment and raised costs for the pharmaceutical industry throughout the world, according to Tony Alvarez, president of MSD KK in Japan, speaking at the in-Pharma Japan and Interphex Japan meetings in Tokyo. He alleged that such agencies, including the U.S. FDA, are deliberately blocking drug research and commercialization as a means of controlling costs.